Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial - Concepedia

Concepedia

Publication | Closed Access

Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial

336

Citations

27

References

2016

Year

Laurie H. Sehn, Neil Chua, Greg Dueck, Marek Trněný, Kamal Bouabdallah, Nathan Fowler, Vincent Delwail, Oliver W. Press, Gilles Salles, John G. Gribben,

The Lancet Oncology

Lymphoid NeoplasiaOncologyCancer TreatmentMedicineRadiation OncologyPhase 3

References

	Year	Citations

Page 1